Imatinib and beyond—the new CML study IVA randomized controlled comparison of imatinib vs imatinib/interferon-alpha vs imatinib/low-dose AraC vs imatinib after interferon-alpha failure in newly diagnosed chronic phase chronic myeloid leukemia

被引：0
|
作者：
U. Berger
G. Engelich
A. Reiter
A. Hochhaus
R. Hehlmann
机构：
[1] Universität Heidelberg,III. Medizinische Universitätsklinik, Klinikum Mannheim
来源：
Annals of Hematology | 2004年 / 83卷
关键词：
Chronic myeloid leukemia; Clinical trial; Imatinib; Interferon alpha; Stem cell transplantation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：258 / 264
页数：6
相关论文
共 30 条
  • [1] Imatinib and beyond - the new CML study IV - A randomized controlled comparison of imatinib vs imatinib/interferon-alpha vs imatinib/low-dose AraC vs imatinib after interferon-alpha failure in newly diagnosed chronic phase chronic myeloid leukemia
    Berger, U
    Engelich, G
    Reiter, A
    Hochhaus, A
    Hehlmann, R
    ANNALS OF HEMATOLOGY, 2004, 83 (04) : 258 - 264
  • [2] Upfront Combined Hydroxyurea and Imatinib versus Imatinib Monotherapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Randomized Controlled Trial
    Chetia, Rituparna
    Palepu, Sarika
    Dutta, Vikramjeet
    Bandyopadhyay, Arkapal
    Mathew, Anisha
    Vaniyath, Sudeep
    Bakliwal, Anamika
    Chattopadhyay, Debranjani
    Rajoreya, Ashok
    Dhamija, Puneet
    Naithani, Manisha
    Singh, Neha
    Nath, Uttam Kumar
    SOUTH ASIAN JOURNAL OF CANCER, 2024,
  • [3] Combination of low-dose imatinib plus nilotinib for the treatment of chronic-phase chronic myeloid leukaemia after imatinib failure
    Gomez-Almaguer, David
    Saldana-Vazquez, Roxana
    Tarin-Arzaga, Luz
    Angel Herrera-Rojas, Miguel
    Vazquez-Mellado de Larracoechea, Alberto
    Graciela Cantu-Rodriguez, Olga
    Homero Gutierrez-Aguirre, Cesar
    Carlos Jaime-Perez, Jose
    Hematology, 2016, 21 (07) : 411 - 414
  • [4] A prospective, randomized study to compare the combination of imatinib and cytarabine versus imatinib alone in newly diagnosed patients with chronic phase chronic myeloid leukemia
    Samal, Priyanka
    Chakrabarti, Prantar
    Nath, Uttam K.
    INDIAN JOURNAL OF CANCER, 2019, 56 (03) : 211 - 215
  • [5] Cost-effectiveness of imatinib versus interferon-α plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia
    Reed, SD
    Anstrom, KJ
    Ludmer, JA
    Glendenning, GA
    Schulman, KA
    CANCER, 2004, 101 (11) : 2574 - 2583
  • [6] Cardiac, Vascular and Hypertension Safety of Bosutinib vs Imatinib for Newly Diagnosed Chronic Myeloid Leukemia in the BFORE Trial
    Cortes, Jorge E.
    Bruemmendorf, Tim H.
    Gambacorti-Passerini, Carlo
    Clark, Richard
    Leip, Eric
    Viqueira, Andrea
    Kota, Vamsi
    Deininger, Michael
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S294 - S295
  • [7] Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenic response after interferon-alpha results in a very high complete molecular response rate
    Alimena, Giuliana
    Breccia, Massimo
    Luciano, Luigia
    Quarantelli, Fabrizio
    Diverio, Daniela
    Izzo, Barbara
    De Angelis, Biagio
    Mancini, Marco
    Latagliata, Roberto
    Carmosino, Ida
    Nanni, Mauro
    Picardi, Marco
    Rotoli, Bruno
    Mandelli, Franco
    Pane, Fabrizio
    LEUKEMIA RESEARCH, 2008, 32 (02) : 255 - 261
  • [8] Long-term survival estimates for imatinib versus interferon-α plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia
    Anstrom, KJ
    Reed, SD
    Allen, AS
    Glendenning, GA
    Schulman, KA
    CANCER, 2004, 101 (11) : 2584 - 2592
  • [9] Updated estimates of survival and cost effectiveness for imatinib versus interferon-α plus low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukaemia
    Reed S.D.
    Anstrom K.J.
    Li Y.
    Schulman K.A.
    PharmacoEconomics, 2008, 26 (5) : 435 - 446
  • [10] Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy
    Kantarjian, Hagop
    O'Brien, Susan
    Garcia-Manero, Guillermo
    Faderl, Stefan
    Ravandi, Farhad
    Jabbour, Elias
    Shan, Jianqin
    Cortes, Jorge
    CANCER, 2012, 118 (12) : 3116 - 3122
123